ArticleJAMA network open2025
Integrating Early Tuberculosis States Into Contact Management in Peru.
Article in JAMA network open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Importance: Tuberculosis (TB) is now understood to exist on a spectrum from TB infection to active TB disease. While World Health Organization guidelines target TB infection and TB disease, they overlook individuals with early TB in the middle of this spectrum. Objective: To evaluate chest radiograph (CR)-guided screening strategies among household contacts (HHCs) of patients with TB in a high-burden setting. Design, Setting, and Participants: This decision analytical model was constructed from June 1 to November 31, 2024. Community-based care in an environment with high TB burden and limited resources was used as the setting in Lima, Peru. Participants included a hypothetical cohort of 1000 HHCs with positive results of a tuberculin skin test and negative results of a sputum culture who were cleared of TB disease based on a clinician's evaluation. The hypothetical cohort was based on the clinical and demographic features of a cohort studied between September 1, 2009, and August 29, 2012. Interventions: Strategy 1 included CR screening to rule out TB disease followed by TB preventive therapy for all; strategy 2, CR screening with treatment for TB disease for those with abnormal CR findings and TB preventive therapy for those without; and strategy 3, observation without pharmacological intervention. We modeled 6 intervention scenarios by applying strategies 1 and 2 to the entire HHC population, to HHCs younger than 35 years, and to HHCs younger than 19 years (Peru's national TB policy). Main Outcomes and Measures: TB cases averted, serious adverse events (SAEs), and drug resistance. Results: A simulated cohort of 1000 HHCs with age and clinical status distributions was based on a previously published cohort of 12 767 TB HHCs in Lima, Peru. Of these, 7661 (60.0%) were male, 4212 (33.0%) were younger than 15 years, and 444 (3.4%) developed TB during 1 year of follow-up. Strategy 2 applied to all HHCs reduced TB cases by 71% to 81%, outperforming strategy 1 applied to all HHCs, which reduced cases by 49% to 69%. Strategy 2 reduced acquired isoniazid resistance but increased SAEs. When both strategies were restricted to HHCs younger than 19 years, strategy 2 reduced TB cases by 42% to 50%. Expanding treatment to older adults further reduced cases but also increased SAEs (19-22 additional SAEs). Conclusions and Relevance: In this model of TB HHC management, CR-guided identification and treatment of early TB was more effective than universal isoniazid preventive therapy, especially in children and young adults. Trade-offs between benefit and harm must be carefully considered in older adults.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.